Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fifth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection
Wen Zhong Liu, Yong Xie, Hong Lü, et al.
Helicobacter (2018) Vol. 23, Iss. 2
Open Access | Times Cited: 370

Showing 1-25 of 370 citing articles:

AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review
Shailja C. Shah, Prasad G. Iyer, Steven F. Moss
Gastroenterology (2021) Vol. 160, Iss. 5, pp. 1831-1841
Open Access | Times Cited: 182
Chinese Consensus Report on Family-BasedHelicobacter pyloriInfection Control and Management (2021 Edition)
Songze Ding, Yiqi Du, Hong Lü, et al.
Gut (2021) Vol. 71, Iss. 2, pp. 238-253
Open Access | Times Cited: 140
2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment
Liya Zhou, Hong Lü, Zhiqiang Song, et al.
Chinese Medical Journal (2022)
Open Access | Times Cited: 114
Evidence-Based Guidelines for the Treatment of <i>Helicobacter pylori</i> Infection in Korea 2020
Hye‐Kyung Jung, Seung Joo Kang, Yong Chan Lee, et al.
Gut and Liver (2021) Vol. 15, Iss. 2, pp. 168-195
Open Access | Times Cited: 110
Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges
Ayman Elbehiry, Eman Marzouk, Musaad Aldubaib, et al.
Antibiotics (2023) Vol. 12, Iss. 2, pp. 191-191
Open Access | Times Cited: 99
Helicobacter pylori World Gastroenterology Organization Global Guideline
Peter Katelaris, Richard H. Hunt, Franco Bazzoli, et al.
Journal of Clinical Gastroenterology (2022) Vol. 57, Iss. 2, pp. 111-126
Open Access | Times Cited: 98
The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management
Ali Nabavi-Rad, Amir Sadeghi, Hamid Asadzadeh Aghdaei, et al.
Gut Microbes (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 76
Global Population Structure, Virulence Factors and Antibiotic Resistance of Helicobacter pylori: A Pooled Analysis of 4067 Isolates From 76 Countries
Mengyi Zhu, Xianfeng Xu, Pengpeng Cai, et al.
Helicobacter (2025) Vol. 30, Iss. 2
Closed Access | Times Cited: 3
Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk Park, Dong‐Hoon Yang, Jong Wook Kim, et al.
Clinical Endoscopy (2020) Vol. 53, Iss. 2, pp. 142-166
Open Access | Times Cited: 116
Recent progress in Helicobacter pylori treatment
Yi Hu, Yin Zhu, Nonghua Lü
Chinese Medical Journal (2020) Vol. 133, Iss. 3, pp. 335-343
Open Access | Times Cited: 90
Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment
Qi Chen, Xiaohua Long, Yingjie Ji, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 49, Iss. 11, pp. 1385-1394
Closed Access | Times Cited: 86
The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults
Cong He, Chao Peng, Huan Wang, et al.
Helicobacter (2019) Vol. 24, Iss. 4
Closed Access | Times Cited: 81
PPI‐amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta‐analysis
Caiping Gao, Di Zhang, Ting Zhang, et al.
Helicobacter (2020) Vol. 25, Iss. 4
Closed Access | Times Cited: 80
The Ideal <b><i>Helicobacter pylori</i></b> Treatment for the Present and the Future
Sho Suzuki, Chika Kusano, Toshiki Horii, et al.
Digestion (2021) Vol. 103, Iss. 1, pp. 62-68
Open Access | Times Cited: 57
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy
Haisheng Qian, Wenjie Li, Yini Dang, et al.
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 4, pp. 627-634
Closed Access | Times Cited: 57
Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study
Yi Hu, Xin Xu, Yaobin Ouyang, et al.
Helicobacter (2022) Vol. 27, Iss. 4
Closed Access | Times Cited: 46
Vonoprazan non‐inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients
Xiaohua Hou, Fandong Meng, Jiangbin Wang, et al.
Journal of Gastroenterology and Hepatology (2022) Vol. 37, Iss. 7, pp. 1275-1283
Open Access | Times Cited: 41
Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis
Biaohua Chen, Puheng Li, Yu Huang, et al.
Pathogens (2022) Vol. 11, Iss. 7, pp. 786-786
Open Access | Times Cited: 41
Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics
Bing Liang, Yang Yuan, Xiaojin Peng, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 40
Amoxicillin‐vonoprazan dual therapy forHelicobacter pylorieradication: A systematic review and meta‐analysis
Yaobin Ouyang, Minghui Wang, Yu‐Ling Xu, et al.
Journal of Gastroenterology and Hepatology (2022) Vol. 37, Iss. 9, pp. 1666-1672
Closed Access | Times Cited: 39
IgY antibodies: The promising potential to overcome antibiotic resistance
Sherif A. El‐Kafrawy, Aymn T. Abbas, Christopher Oelkrug, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 35
Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China
Jie Hu, Hao Mei, Na‐Yun Su, et al.
Helicobacter (2023) Vol. 28, Iss. 4
Closed Access | Times Cited: 34
Gastric microbiota in gastric cancer: Different roles of Helicobacter pylori and other microbes
Yang Guo, Xueshan Cao, Mengge Zhou, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 12
Open Access | Times Cited: 32
Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study
Yi Hu, Xin Xu, Xiao‐Shun Liu, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 28
Is Tailored Bismuth Quadruple Therapies (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial
Zhengchen Yu, Xiaochen Liu, Jincheng Qiao, et al.
Helicobacter (2025) Vol. 30, Iss. 1
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top